Targeted Antigen Therapies and Immunity

• 2649 · PDF Tumor endothelial cell and cancer cell targeting anti-PRND antibody-drug conjugate to treat hypervascular tumors such as glioblastoma and sarcomas Byoungmo Kim, Ha Kyeong Lee, So-Young Choi, Sera Lee, Sang Yoon Kim, Youngro Byun, Seong Who Kim
• 2650 · PDF Breaking immune silence: Tumor-targeted molecular therapy reprograms the tumor-immune interface in progressive neuroblastoma Loganayaki Periyasamy, Sreenidhi Mohanvelu, Sheeja Aravindan, Poorvi Subramanian, Natarajan Aravindan
• 2652 · PDF MGT-1142, an antibody-drug conjugate targeting a novel glycan for small-cell lung cancer Su-Yu Tsai, Maomao He, Ju-Mei Li, Ping Chao, Ting-Chun Hung, Mei-Hsuan Tsai, Charng-Sheng Tsai
• 2653 · PDF Sequencing immune checkpoint inhibitors and BRAF/MEK inhibitors in advanced melanoma: A meta-analysis of Kaplan-Meier-reconstructed individual level data Anderson Ruiz Simoes, Isabella Michelon, Wellington Neto, Metamia Ciampricotti, Ludimila Cavalcante
• 2654 · PDF DB-1421, an optimized EGFR/MUC1 bispecific ADC, exhibits improved tumor selectivity, promising efficacy and safety in preclinical studies Chenggang Li, Jun Yao, Yongsheng Nie, YANG QIU, Haiqing Hua
• 2655 · PDF DB-1323, a next-generation mesothelin targeting antibody-drug conjugate, demonstrated anti-tumor activity and favorable safety profile in pre-clinical models Haiqing Hua, Xi Li, Jun Yao, Tao Cheng, Junjie Yang, Xinyue Chen, Sang Pil Lee, Jiyoung Shin, Yunseon Choi, Gisun Baek, Alexandre Joyeux, Jung Chae Lim
• 2656 · PDF DB-1329: A novel antibody-drug conjugate targeting CDCP1 demonstrates potent preclinical anti-tumor activity across multiple solid tumors Hui Yang, Yujie Liu, YANG QIU, Haiqing Hua
• 2657 · PDF DB-1326, a novel dual-payload TA-MUC1-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model Chenggang Li, Lei Yi, Jun Yao, Yang Qiu, Haiqing Hua
• 2658 Distinct biological and immune microenvironment features of MSI-H BRAF V600E colorectal cancer: Potential for combined PD‑1, BRAF, and EGFR inhibition Lulu He, Feng Guo
• 2659 · PDF CD44v9-targeted antibody-drug conjugate as a novel therapy for advanced breast cancer Dileep R. Reddy, McKenna E. Flynn, Yasuaki Anami, Zhaoxuan Yang, Jayden Aleman, Minji Seo, Kyoji Tsuchikama, Jennifer A. Maynard, Naoto T. Ueno, Jangsoon Lee
• 2660 · PDF AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers Sunil Bhakta, Levi Blazer, Cristina Abrahams, Jiang Liu, Coen Kuijl, Jarrett Adams, Marcin Kowanetz, Luna Musib, Amy Kim, Wanda Kwan, Viswanatham Katta, Vidya S. Jonnalagadda, Reva Raghupathi, Paul Polakis, Stuart Lutzker, Sachdev S. Sidhu, Jagath Reddy Junutula
• 2661 · PDF AZD5335, a folate receptor alpha-targeted ADC, exerts anti-tumor responses within lung adenocarcinoma Jason J. Zoeller, Ravinder Tammali, Nancy Lee, Isabella Tilmont, Judith Anderton, Shailesh Metkar, Michael Ophir, Jixin Wang, Claire Myers, Lara McGrath, Alma Andoni, Ina Bisha, Iris Dino, Xhenifer Guza, Simon Christ, Michael Lehmann, Roger Dodd, Neki Patel, Tim Brier, Marc L. Hyer, Marco Gymnopoulos, Sabina Cosulich, Alejandra Negro, Elaine Hurt, Puja Sapra
• 2662 · PDF MGT-1141, an antibody-drug-conjugate targeting DLL3 positive cancers Mei-Hsuan Tsai, Maomao He, Su-Yu Tsai, Ju-Mei Li, Ping Chao, Ting-Chun Hung, Charng-Sheng Tsai
• 2663 · PDF Targeting YAP/TEAD signaling disturbs RNA polymerase II activity and enhances immunotherapy response via activated cytosolic DNA sensing pathway in gastroesophageal cancer Yanting Yann Zhang, Ayna Mammedova, Dipti Athavale, Curt Balch, Mikel Ghelfi, Xiaodan Yao, Gennaro Calendo, Songjie Liu, David Pulipati, Yahui Li, Xiaoxin Chen, Francis Spitz, Generosa Grana, Vladimir Khazak, Shumei Song
• 2664 · PDF MGT-1143, a novel CDH17-targeting ADC for gastrointestinal cancers Maomao He, Ping Chao, Su-Yu Tsai, Ju-Mei Li, Ting-Chun Hung, Mei-Hsuan Tsai, Charng-Sheng Tsai
• 2665 · PDF The MET/HER3 antibody-drug conjugate with dual payload: A dual-target approach to eliminate tumor escape mechanism Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen
• 2666 · PDF An open-label, multicenter Phase I clinical study of CVL006, a novel PD-L1/VEGF bispecific antibody, in advanced solid tumors Jin Li, Ning Li, Shuhang Wang, Ye Guo, Kai Yao, Yanjie Zhu, Feng Ye, Hao Zeng, Steve Shen, Jin Zhang
• 2667 · PDF TM4SF1 as a novel tumor-associated antigen in biliary tract cancers targetable by immune effector cell therapy Lorraine Nuniz*, Julia Pham, Juliette Jacques, Josephine Hinneh, Jocelin Chen, Corynn Kasap, Jon Akutagawa, Chih-Hao Chang, Robin K. Kelley, Arun Wiita, Jonathan Chou, Kwun Wah Wen, Vipul Kumar*, Franklin Huang
• 2671 · PDF TROP2 expression predicts sensitivity to datopotamab deruxtecan (Dato-DXd) in patient-derived breast cancer organoids Won-Ji Ryu, Min Hwan Kim, Geon-Uk Kim Kim, Joohyuk Sohn, Yumi Hwang, Jeong Dong Lee, Shinyoung Park, Hyun Myoung Yun, Kyoo Hyun Kim, Gun Min Kim, Hyung Seok Park
• 2672 · PDF Characterization of small molecule inhibitors against Lipocalin-2 in inflammatory breast cancer Sthephanie Estrada-Mojica, Fatma Valiyeva, Pablo E. Vivas Mejia

在完整检索应用中浏览本分会场 →